Alpha-Lipoic Acid for Women: Are There Any Special Considerations

Alpha-lipoic acid (ALA) is often marketed to women as an “antioxidant for beauty” and a “weight-loss aid.” Our editorial team examined whether the female body really responds to this supplement differently, which studies were conducted specifically with women, and in which situations ALA is best avoided.

What alpha-lipoic acid is and why the body needs it

Alpha-lipoic (thioctic) acid is a small sulfur-containing molecule that human cells synthesize on their own in the mitochondria. There it works as a cofactor for the enzyme complexes pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, without which the normal “burning” of glucose and fatty acids for energy would be impossible. So in physiological amounts ALA is part of the basic energy metabolism that is equally important for men and women.

A supplement in capsule form is a different story. Taken orally, free ALA is absorbed quickly, peaks in plasma in about half an hour, and is eliminated just as quickly. During this brief window it displays antioxidant properties: both the acid itself and its reduced form — dihydrolipoic acid — can neutralize reactive oxygen species and regenerate other antioxidants, in particular glutathione and vitamin C.

In food, ALA is present in a protein-bound form, mainly in organ meats (liver, kidney, heart), as well as in spinach and broccoli. The amounts there are small, so the doses used in clinical trials (hundreds of milligrams per day) cannot be obtained from food. That is precisely why the supplement’s effects should not be automatically transferred to the “natural” ALA in the diet.

In European countries, particularly Germany, ALA has been used for decades as a medicine for diabetic polyneuropathy. The most evidence has accumulated in exactly this area: in the SYDNEY 2 trial, an oral dose of 600 mg per day reduced neurological symptoms compared with placebo. Other claimed effects — for weight, skin, or “rejuvenation” — have a much weaker evidence base.

Does ALA act differently in women

The short answer: science knows of no special “female” mechanisms of action for alpha-lipoic acid. The molecule works in the mitochondria and in antioxidant systems that are arranged the same way regardless of sex. Our editors found no separate pharmacokinetic studies that would show a clinically significant difference in the absorption or elimination of ALA between men and women.

At the same time, there are factors that indirectly influence the outcome. Women on average have a lower body weight, so the same dose in milligrams means a larger dose per kilogram. In addition, women more often have conditions that ALA can potentially affect: insulin resistance against the background of polycystic ovary syndrome (PCOS), autoimmune thyroid disease, and use of hormonal contraceptives.

Most clinical studies of ALA were conducted in mixed samples, where women made up a significant share of participants, but the results were rarely analyzed separately by sex. So claims such as “ALA works better in women” or “women need a lower dose” have no direct confirmation — these are marketing generalizations.

The editorial team’s practical takeaway: for a woman, the general rules for taking ALA are the same as for a man, but it is worth checking accompanying conditions and medications more carefully, because it is precisely these that most often determine whether the supplement makes sense and whether it is safe.

Weight, insulin, and polycystic ovary syndrome

The most popular “female” query about ALA is weight loss. In a randomized trial by Koh and colleagues (2011), obese adults, many of them women, took 1200 or 1800 mg of ALA per day for 20 weeks. In the higher-dose group, body weight dropped a little more than on placebo, but the difference was only a few percent and did not exceed the effect of an ordinary diet.

A meta-analysis by Kucukgoncu and colleagues (2017) confirmed that the additional weight loss with ALA compared with placebo averages about one kilogram. For a person with obesity this is statistically noticeable but clinically modest. For a woman of normal weight who wants to “lean out,” there is no basis for expecting a tangible effect from ALA.

A more interesting topic is insulin resistance. Small studies involving patients with type 2 diabetes (in particular the work of Jacob et al., 1999) showed a moderate improvement in insulin sensitivity with ALA. In PCOS, insulin resistance is often one of the key mechanisms behind cycle disturbances, so the hypothesis that ALA might help looks logical.

A pilot study by Masharani and colleagues (2010) in lean women with PCOS showed improvement in some measures of insulin sensitivity and triglycerides after taking controlled-release ALA. However, the sample was very small, and there was no placebo group. Such data are a reason for further research, not grounds for replacing treatment prescribed by a gynecologist or endocrinologist with a supplement.

• ALA is not a treatment for PCOS and is not part of standard clinical guidelines.
• The foundation for correcting insulin resistance remains diet, physical activity, and, where indicated, medication.
• If a woman is taking metformin or other glucose-lowering agents, adding ALA must be coordinated with a doctor because of the risk of excessive lowering of glucose.

Pregnancy, lactation, and drug interactions

During pregnancy and breastfeeding, any supplements beyond the standard ones (folic acid, iodine, vitamin D as prescribed) should be considered with caution. For ALA there are individual clinical observations in pregnant women, but there are no large safety studies. So the standard position is not to take ALA during these periods without a direct recommendation from a doctor.

The second important topic is the thyroid gland. Thyroid diseases, in particular autoimmune thyroiditis, occur noticeably more often in women than in men, and many of them take levothyroxine. ALA can form complexes with metal ions and could theoretically affect the absorption of other drugs, so it is sensible to space the supplement and the thyroid hormone apart in time and to monitor TSH after starting.

The third point is glucose-lowering drugs. Since ALA can slightly enhance glucose utilization, combining it with insulin or sulfonylurea drugs theoretically increases the risk of hypoglycemia. For a healthy woman this is unlikely, but for a patient with diabetes it is a real concern.

Finally, ALA is often included in “female” complexes together with biotin, collagen, and plant extracts. Biotin in high doses can distort the results of laboratory tests, in particular thyroid hormones. Before having tests done, it is worth telling your doctor about all supplements, and biotin-containing products are usually advised to be stopped a few days before blood is drawn.

Safety: what women should watch for

In clinical studies with doses up to 600 mg per day, ALA was well tolerated. The most common complaints are nausea and stomach discomfort, less often a skin rash. At higher doses (1200–1800 mg), gastrointestinal symptoms occurred more often, so “more” in this case does not mean “better.”

A rare but serious risk is insulin autoimmune syndrome (Hirata disease). This is a condition in which the body produces antibodies to its own insulin, causing episodes of severe hypoglycemia. Cases associated with taking ALA have been described, primarily in people with certain HLA genetic variants; such variants are more common in East Asian populations, but cases have also been described in Europeans (Gullo et al., 2014).

Symptoms that should prompt you to stop taking it and see a doctor: trembling, sweating, palpitations, intense hunger, or confusion, especially on an empty stomach or a few hours after eating. Women often write off such manifestations as “low blood pressure” or fatigue, so it is important to know about this connection.

ALA also gives urine a specific odor, which is not dangerous but sometimes frightening. Chronic alcohol abuse and thiamine deficiency are situations where self-administration of high doses of ALA is undesirable, since both conditions affect the same enzyme systems.

Editorial conclusions

Alpha-lipoic acid has no proven “female specificity”: the mechanism of action and the overall safety profile are the same for both sexes. Differences arise from accompanying conditions, body weight, and medications that women take more often.

For weight loss, ALA provides only a symbolic addition to the effect of a diet. Data on PCOS and insulin resistance are interesting but preliminary, and the supplement does not replace treatment.

The most important thing from a practical standpoint is not to take ALA during pregnancy and lactation without a doctor, to space dosing apart from levothyroxine, and to keep in mind the risk of hypoglycemia and the rare Hirata syndrome.

If this topic interests you, we also recommend reading our articles “Alpha-Lipoic Acid After 40,” “Alpha-Lipoic Acid During Cutting: Does It Help,” and “CLA for Women: Are There Any Special Considerations.”

References

1. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160.
2. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370.
3. Koh EH, Lee WJ, Lee SA, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011;124(1):85.e1–85.e8.
4. Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev. 2017;18(5):594–601.
5. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999;27(3–4):309–314.
6. Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010;4(2):359–364.
7. Gullo D, Evans JL, Sortino G, Goldfine ID, Vigneri R. Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking α-lipoic acid. Clin Endocrinol (Oxf). 2014;81(2):204–209.